Last reviewed · How we verify
Lorcaserin HCl
Lorcaserin HCl is a 5-HT2C receptor agonist Small molecule drug developed by Beth Israel Deaconess Medical Center. It is currently FDA-approved for Chronic weight management in obese or overweight adults with weight-related comorbidities. Also known as: Belviq, placebo Belviq, Belviq XR®.
Lorcaserin is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.
Lorcaserin is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite. Used for Chronic weight management in obese or overweight adults with weight-related comorbidities.
At a glance
| Generic name | Lorcaserin HCl |
|---|---|
| Also known as | Belviq, placebo Belviq, Belviq XR® |
| Sponsor | Beth Israel Deaconess Medical Center |
| Drug class | 5-HT2C receptor agonist |
| Target | 5-HT2C receptor |
| Modality | Small molecule |
| Therapeutic area | Obesity/Weight Management |
| Phase | FDA-approved |
Mechanism of action
Lorcaserin selectively binds to and activates the 5-HT2C receptor in the hypothalamus, a brain region that regulates appetite and energy expenditure. This activation leads to decreased hunger signals and increased feelings of fullness, resulting in reduced caloric intake and weight loss. The selectivity for 5-HT2C over other serotonin receptors (particularly 5-HT2B) was designed to minimize cardiac valvulopathy risk associated with non-selective serotonergic agents.
Approved indications
- Chronic weight management in obese or overweight adults with weight-related comorbidities
Common side effects
- Headache
- Dizziness
- Nausea
- Fatigue
- Dry mouth
Key clinical trials
- Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
- Lorcaserin in Obesity: Identification of CNS Targets Using FMRI (PHASE4)
- Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years (PHASE4)
- Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer (PHASE1)
- Lorcaserin in the Treatment of Cocaine Use Disorder (PHASE2)
- Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder (PHASE1)
- BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management (PHASE3)
- BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lorcaserin HCl CI brief — competitive landscape report
- Lorcaserin HCl updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI
Frequently asked questions about Lorcaserin HCl
What is Lorcaserin HCl?
How does Lorcaserin HCl work?
What is Lorcaserin HCl used for?
Who makes Lorcaserin HCl?
Is Lorcaserin HCl also known as anything else?
What drug class is Lorcaserin HCl in?
What development phase is Lorcaserin HCl in?
What are the side effects of Lorcaserin HCl?
What does Lorcaserin HCl target?
Related
- Drug class: All 5-HT2C receptor agonist drugs
- Target: All drugs targeting 5-HT2C receptor
- Manufacturer: Beth Israel Deaconess Medical Center — full pipeline
- Therapeutic area: All drugs in Obesity/Weight Management
- Indication: Drugs for Chronic weight management in obese or overweight adults with weight-related comorbidities
- Also known as: Belviq, placebo Belviq, Belviq XR®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing